9-(2-Chlor-2-deoxy-β-D-arabinofuranosyl) adenin | 2627-62-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 9-(2-Chlor-2-deoxy-β-D-arabinofuranosyl) adenin
• 英文别名: (2R,3R,4S,5R)-5-(6-aminopurin-9-yl)-4-chloro-2-(hydroxymethyl)oxolan-3-ol
• CAS: 2627-62-5；4227-33-2；4555-79-7；59263-40-0
• 化学式: C₁₀H₁₂ClN₅O₃
• 分子量: 285.69
• InChiKey: ADXUXRNLBYKGOA-GQTRHBFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  9-(2-Chlor-2-deoxy-β-D-arabinofuranosyl) adenin 在 吡啶 、 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 甲苯 为溶剂， 反应 2.5h， 生成 5'-O-(tert-butyldimethylsilyl)-2'-deoxyadenosine
  参考文献：
  名称：

  Nucleic Acid Related Compounds. 91. Biomimetic Reactions Are in Harmony with Loss of 2‘-Substituents as Free Radicals (Not Anions) during Mechanism-Based Inactivation of Ribonucleotide Reductases. Differential Interactions of Azide, Halogen, and Alkylthio Groups with Tributylstannane and Triphenylsilane¹

  摘要：

  The initial step in the mechanism-based inactivation of ribonucleotide reductases by 2'-chloro-2'-deoxynucleotides is abstraction of H3' by a proximal free radical on the enzyme. The C3' radical is postulated to undergo spontaneous loss of chloride, and the resulting cationic radical loses a proton to give a 3'-keto intermediate. Successive beta-eliminations produce a Michael acceptor which causes inactivation. This hypothesis would predict rapid loss of mesylate or tosylate anions from C2', but sluggish loss of azide or thiomethoxide. in contrast, loss of azido and methylthio radicals from C2' should occur readily whereas homolysis to give (methyl or tolylsulfonyl)oxy and fluoro radicals should be energetically prohibitive. Protected 3'-O-(phenoxythiocarbonyl)-2'-substitute nucleosides were treated with tributylstannane/AIBN or triphenylsilane/dibenzoyl peroxide in refluxing toluene. The 2'-O-(mesyl and tosyl) and 2'-fluoro compounds underwent direct radical-mediated hydrogenolysis of the thionocarbonate group to give 3'-deoxy-2'-substituted products, whereas 2'-(azido, bromo, chloro, iodo, and methylthio)-3'-thionocarbonates gave 2',3'-didehydro-2',3'-dideoxy derivatives via loss of 2'-substituents from an incipient C3' radical. These results are in harmony with loss of radicals, but not anions, from C2'. The well-known radical-mediated hydrogenolytic cleavage of halogen and methylthio (slow) groups from C2' of the S'-hydroxy (unprotected) precursors and reduction of 2'-azides to amines occurred with tributylstannane/AIBN. Triphenylsilane/dibenzoyl peroxide gave parallel (but slower) hydrogenolysis with the 2'-(iodo, bromo, and methylthio) compounds, but cleavage of the 2'-chloro group was very slow and no reduction of 2'-azides to amines was detected. Rather, the latter system effected slow hydrogenolytic removal of the 2'-azido group. Thus, chemoselective differentiation of certain functional groups is possible with triphenylsilane and tributylstannane. Reduction of azides to amines with tributylstannane is known, but hydrogenolytic deazidation (slow) with triphenylsilane in the absence of amine formation appears to be novel.

  DOI：

  10.1021/ja962117m
• 作为产物：
  描述：

  2'-O-triflyl-3',6'-O-(tetraisopropyldisiloxane-1,3-diyl)-adenosine 在 四丁基氟化铵 、 lithium chloride 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 为溶剂， 反应 5.17h， 生成 9-(2-Chlor-2-deoxy-β-D-arabinofuranosyl) adenin
  参考文献：
  名称：

  Synthesis of 2'-substituted derivatives of neplanocin A (Nucleosides and nucleotides. XLIV).

  摘要：

  Neplanocin A（1）和 N6-苯甲酰基eplanocin A（2）被转化为相应的 3'，6'-O-（四异丙基二硅氧烷-1，3-二基）-eplanocin A（3，4）。3 和 4 中的 2'-羟基被三氟化（5，6）。在六甲基磷酸三酰胺中，用多种亲核剂（I-、Br-、Cl-、N3-、AcO-、AcS-）对 5 和 6 进行亲核置换，可以高产率得到相应的 2' (R)-取代衍生物。用这种方法制备的阿糖胞苷 A 也以类似的方式得到了 2' (S)-叠氮衍生物。腺苷也被转化为 2' (R)-取代的衍生物，包括阿拉伯呋喃糖基腺嘌呤，以及 2' (S)-取代的腺苷。文中介绍了这些 2'-取代的肾上腺素 A 和腺苷衍生物的物理性质，包括核磁共振和圆二色光谱。

  DOI：

  10.1248/cpb.31.1582

文献信息

• [EN] COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT D'ADMINISTRER DES AGENTS THÉRAPEUTIQUES
  申请人：MODERNATX INC

  公开号：WO2017099823A1

  公开（公告）日：2017-06-15

  This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

  这项披露提供了改进的基于脂质的组合物，包括脂质纳米粒子组合物，以及它们用于体内传递药剂的方法，包括核酸和蛋白质。这些组合物不受加速血清清除的影响，并且它们在体内具有改进的毒性特性。
• [EN] MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF<br/>[FR] MOLÉCULES D'ACIDE NUCLÉIQUE MODIFIÉES ET LEURS UTILISATIONS
  申请人：MODERNA THERAPEUTICS INC

  公开号：WO2014093924A1

  公开（公告）日：2014-06-19

  The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

  本公开提供了经修改的核苷、核苷酸和核酸，以及它们的使用方法。
• [EN] TRANSLATIONAL ENHANCERS AND RELATED METHODS<br/>[FR] AMPLIFICATEURS DE TRADUCTION ET PROCÉDÉS ASSOCIÉS
  申请人：EFFECTOR THERAPEUTICS INC

  公开号：WO2021001739A1

  公开（公告）日：2021-01-07

  The present disclosure relates to novel translational enhancers comprising an eukaryotic initiation factor 4E (eIF4E) ligand attached to a dinucleotide. The present disclosure also relates to RNA molecules (e.g., mRNAs) comprising the novel translational enhancers, which imparts properties to the RNA molecules that are advantageous to therapeutic development, methods of using RNA molecules comprising such novel translational enhancers for therapeutic uses, as well as kits containing the translational enhancers.

  本公开涉及包含连接到二核苷酸的真核起始因子4E（eIF4E）配体的新型转译增强剂。本公开还涉及包含这些新型转译增强剂的RNA分子（例如mRNA），这些RNA分子赋予了对治疗开发有利的特性，以及使用包含这些新型转译增强剂的RNA分子进行治疗用途的方法，以及包含转译增强剂的试剂盒。
• [EN] POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA<br/>[FR] POLYNUCLÉOTIDES CODANT POUR LA LIPOPROTÉINE LIPASE DESTINÉS AU TRAITEMENT DE L'HYPERLIPIDÉMIE
  申请人：MODERNATX INC

  公开号：WO2017201333A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of hyperlipidemia. mRNAs for use in the invention, when administered in vivo, encode human lipoprotein lipase (LPL), isoforms thereof, functional fragments thereof, and fusion proteins comprising LPL. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto, mRNA therapeaies of the invention increase and/or restore deficient levels of LPL expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of triglycerides associated with deficient LPL activity in subjects.

  该发明涉及mRNA疗法用于治疗高脂血症。该发明中使用的mRNA，在体内给予时，编码人类脂蛋白脂肪酶（LPL）、其异构体、其功能性片段以及包含LPL的融合蛋白。该发明中的mRNA最好被封装在脂质纳米颗粒（LNPs）中，以实现对受试者的细胞和/或组织的高效传递，当给予治疗时，该发明中的mRNA疗法增加和/或恢复受试者中LPL表达和/或活性的不足水平。该发明中的mRNA疗法进一步降低与受试者中LPL活性不足相关的甘油三酯水平。
• [EN] POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME<br/>[FR] POLYNUCLÉOTIDES CODANT POUR JAGGED1 POUR LE TRAITEMENT DU SYNDROME D'ALAGILLE
  申请人：MODERNATX INC

  公开号：WO2017201342A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG1), isoforms thereof, functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.

  该发明涉及用于治疗艾拉吉尔综合征（ALGS）的mRNA疗法，该发明中使用的mRNA，在体内给予时，编码JAGGED 1（JAG1）、其同工异构体、其功能性片段以及包含JAG1的融合蛋白，该发明的mRNA最好被封装在脂质纳米颗粒（LNPs）中，以实现对受试者的细胞和/或组织的有效传递，当向受试者施用时。该发明的mRNA疗法增加和/或恢复受试者中JAG1表达和/或活性的不足水平。该发明的mRNA疗法进一步降低与受试者中JAG1活性不足相关的有毒代谢物水平。